Adv. Zemach is a partner in the International Corporate and Securities Department. His broad-based transactional practice concentrates on mergers and acquisitions, capital markets transactions and corporate governance matters, and he has been involved in numerous high-profile and complex international transactions, including struggles for corporate control and shareholder activism, valued at a total of over $100 billion.
Adv. Zemach advises emerging companies as well as public companies, including committees of independent directors, investment banks, private equity and VC funds, on a broad array of corporate and securities law matters as well as domestic and cross-border transactions, including M&As; public offerings; venture capital investments; technology licensing; and franchise transactions in a variety of industries, including technology, media and telecommunications (TMT), life sciences, cyber, gaming, energy, aviation, food and retail, spreading over diverse geographies, including the U.S., Europe, China and Japan.
Adv. Zemach has acted in the past few years in a number of significant corporate transactions involving the representation of a range of domestic and foreign companies, including Attunity (Nasdaq: ATTU) on its sale to Qlik (a Thoma Bravo company); Comtech Telecommunications (Nasdaq: CMTL) on its pending acquisition of Gilat Satellite (Nasdaq: GILT); Google on its acquisition of Waze; Intel on its acquisition of Replay Video; Itamar Medical (Nasdaq: ITMR) on its Nasdaq IPO; J.P. Morgan, Barclays, Jefferies and the other underwriters on the IPO of Tufin Software (Nasdaq: TUFN); Micron (Nasdaq: MU) on its acquisition of Numonyx and the sale of Israeli plant to Intel; Mitsubishi Tanabe Pharma on its acquisition of NeuroDerm (Nasdaq: NDRM); Ormat Industries (TASE: ORMT) on its reorganization with Ormat Technologies (NYSE: ORA); Radware (Nasdaq: RDWR) on its acquisitions of ShieldSquare, Seculert and Strangeloop; Signet Jewelers (NYSE: SIG) on its acquisition of R2Net; and TCV on its investment in Payoneer.
Adv. Zemach routinely advises boards of directors and management teams on their most sensitive and crucial matters, devising creative solutions to achieve their goals, including the structuring of the first U.S. style shareholder rights plan (a/k/a ‘poison pill’) ever adopted by an Israeli company and the first special tender offer conducted for a dual listed company.
Adv. Zemach was recognized as a leading M&A and capital markets attorney by a number of international guides and occasionally publishes professional articles and lectures on different aspects of his practice areas at academic and professional forums.
Adv. Zemach is an LL.B. graduate of the Hebrew University and a LL.M. graduate of Fordham University, New York. Following law school, he clerked for the Tel Aviv District Attorney (Fiscal Department). From 1999 to 2000, Adv. Zemach was an associate at the corporate department of Wachtell, Lipton, Rosen & Katz, New York.
LL.M., Banking, Corporate and Finance Law, Fordham University, New York, 1999
LL.B., Hebrew University of Jerusalem, 1996
Israel Bar Association, 1997
New York Bar Association, 2000
"An excellent lawyer."
Chambers & Partners | 2021
"A very, very good M&A lawyer."
Chambers & Partners | 2020
"Thoughtful and extremely efficient in his approach to transactions. Cuts to the chase quickly.”
The Legal 500 | 2020
"Extraordinarily smart, practical and incredibly client-focused."
Chambers & Partners | 2019